Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children

Clinical trial NCT07318831 · RECRUITING

Trial details

NCT number: NCT07318831
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Neuroblastoma (NB)Neuroblastoma in Children

Start date: 2026-01-06
Primary completion: 2028-12-31
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.